Cargando…

Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients

The discovery of angiotensin converting enzyme-2 (ACE-2) as the receptor for SARS- CoV-2 (Severe Acute Respiratory Syndrome Coronavirus-2) has implicated the renin-angiotensin-aldosterone system in acute respiratory distress syndrome (ARDS) and respiratory failure in patients with coronavirus diseas...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rossi, Gian Paolo, Sanga, Viola, Barton, Matthias
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	eLife Sciences Publications, Ltd 2020
Materias:	Human Biology and Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7198232/ https://www.ncbi.nlm.nih.gov/pubmed/32250244 http://dx.doi.org/10.7554/eLife.57278

Ejemplares similares

Controversy regarding ACE inhibitors / ARBs in COVID-19
por: Soria Arcos, Federico, et al.
Publicado: (2020)

ACE2 localizes to the respiratory cilia and is not increased by ACE inhibitors or ARBs
por: Lee, Ivan T., et al.
Publicado: (2020)

COVID-19-related deaths not increased with ACE inhibitor or ARB use
Publicado: (2020)

The effect of ACE inhibitors and ARBs on outcomes in hospitalized patients with COVID-19
por: Najafi, Narges, et al.
Publicado: (2022)

Angiotensin-Converting Enzyme (ACE) Inhibitors and Angiotensin Receptor Blockers (ARB) Are Protective Against ICU Admission and Mortality for Patients With COVID-19 Disease
por: ElAbd, Rawan, et al.
Publicado: (2021)

ASSOCIATION BETWEEN IN-HOSPITAL MORTALITY AND ACE/ARB INHIBITOR USAGE
por: Ruge, Max, et al.
Publicado: (2022)

ACE-inhibitor/angiotensin receptor blockers (ACE-I/ARBs) therapy in COVID-19 infected dialysis patients
por: Daoud, Ahmed, et al.
Publicado: (2021)

The influence of ACE inhibitors and ARBs on hospital length of stay and survival in people with COVID-19
por: Braude, Philip, et al.
Publicado: (2020)

Hospital mortality in COVID-19 patients in Belgium treated with statins, ACE inhibitors and/or ARBs
por: Byttebier, Geert, et al.
Publicado: (2021)

What Evidence Supports Guidelines for Use of ACE Inhibitors and ARBs in Diabetes?
por: Curtiss, Frederic R.
Publicado: (2006)

Continue ACE inhibitors / ARB’S till further evidence in coronavirus disease 2019 (COVID-19)
por: Bansal, Sandeep, et al.
Publicado: (2020)

Treatment with ACE inhibitors or ARBs and risk of severe/lethal COVID-19: a meta-analysis
por: Flacco, Maria Elena, et al.
Publicado: (2020)

NO EXCESS MORTALITY ASSOCIATED WITH CONCOMITANT ACE INHIBITOR OR ARB USE IN HOSPITALIZED PATIENTS WITH COVID-19
por: Annie, Frank H., et al.
Publicado: (2021)

The concern about ACE/ARB and COVID-19: Time to hold your horses!
por: Pergolizzi, Joseph V., et al.
Publicado: (2020)

ACE Inhibitor and ARB Utilization and Expenditures in the Medicaid Fee-For-Service Program from 1991 to 2008
por: Bian, Boyang, et al.
Publicado: (2010)

COVID-19: The Influence of ACE Genotype and ACE-I and ARBs on the Course of SARS-CoV-2 Infection in Elderly Patients
por: Sieńko, Jerzy, et al.
Publicado: (2020)

Angiotensin-converting-enzyme inhibitors (ACE inhibitors) and angiotensin II receptor blocker (ARB) use in COVID-19 prevention or treatment: A paradox
por: Javanmard, Shaghayegh Haghjooy, et al.
Publicado: (2020)

Association of ACEi/ARB Use and Clinical Outcomes of COVID-19 Patients With Hypertension
por: Ma, Jing, et al.
Publicado: (2021)

BRAF inhibitors suppress apoptosis through off-target inhibition of JNK signaling
por: Vin, Harina, et al.
Publicado: (2013)

ACEI inhibitors and ARBs do not increase severity of COVID-19
Publicado: (2020)

Registered report: RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
por: Bhargava, Ajay, et al.
Publicado: (2016)

COVID-19 medical papers have fewer women first authors than expected
por: Andersen, Jens Peter, et al.
Publicado: (2020)

Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome
por: van de Veerdonk, Frank L, et al.
Publicado: (2020)

A distinct p53 target gene set predicts for response to the selective p53–HDM2 inhibitor NVP-CGM097
por: Jeay, Sébastien, et al.
Publicado: (2015)

Correction: A distinct p53 target gene set predicts for response to the selective p53-HDM2 inhibitor NVP-CGM097
por: Jeay, Sébastien, et al.
Publicado: (2016)

Safety of ACE-I and ARB medications in COVID-19: A retrospective cohort study of inpatients and outpatients in California
por: Rubin, Samuel J. S., et al.
Publicado: (2021)

Augmented curation of clinical notes from a massive EHR system reveals symptoms of impending COVID-19 diagnosis
por: Wagner, Tyler, et al.
Publicado: (2020)

Cardiovascular risk reduction by reversing endothelial dysfunction:ARBs, ACE inhibitors, or both? Expectations from The ONTARGET Trial Programme
por: Ruilope, Luis Miguel, et al.
Publicado: (2007)

Aliskiren: Just a New Drug for Few Selected Patients or an Innovative Molecule Predestinated to Replace Arbs and Ace-Inhibitors?
por: Novo, Salvatore, et al.
Publicado: (2009)

Mortality and Severity in COVID-19 Patients on ACEIs and ARBs—A Systematic Review, Meta-Analysis, and Meta-Regression Analysis
por: Singh, Romil, et al.
Publicado: (2022)

The emerging neurobiology of calorie addiction
por: García-Cáceres, Cristina, et al.
Publicado: (2014)

ACE-I/ARB Therapy prior to Contrast Exposure: What Should the Clinician Do?
por: Kalyesubula, Robert, et al.
Publicado: (2014)

SARS-CoV-2 downregulation of ACE2 and pleiotropic effects of ACEIs/ARBs
por: Ciulla, Michele M.
Publicado: (2020)

Communication in the Time of COVID-19
por: Chekijian, Sharon
Publicado: (2021)

149 Association of ACE-I and ARB Prescriptions With Mortality in Patients Admitted to the Hospital With COVID-19 in New York City
por: Barrett, B., et al.
Publicado: (2020)

Rhodopsin targeted transcriptional silencing by DNA-binding
por: Botta, Salvatore, et al.
Publicado: (2016)

Impact of Beta-blocker, ACE Inhibitor, and ARB therapy on thoracic aorta wall shear stress in bicuspid aortic valve patients
por: McGee, Katherine, et al.
Publicado: (2016)

Centrally acting ACE inhibitor (cACEi) and angiotensin receptor blocker (cARB) use and cognitive dysfunction in patients with SLE
por: Dobrowolski, Chrisanna, et al.
Publicado: (2023)

Antihypertensive medication uses and serum ACE2 levels: ACEIs/ARBs treatment does not raise serum levels of ACE2
por: Emilsson, Valur, et al.
Publicado: (2020)

ACE-I AND ARBS DO NOT INFLUENCE THE CHEST CT PRESENTATION AND 1-YEAR SURVIVAL OF COVID-19 PATIENTS: ITALIAN MULTICENTER REGISTRY
por: Birtolo, Lucia Ilaria, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_acsj6r9m6mjk9ejqu89pnbfklg